Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	23.29	9.56	19.87	35.7	57.17
Cash & Short-Term Investments	23.29	9.56	19.87	35.7	57.17
Cash Growth	143.48%	-51.85%	-44.36%	-37.54%	438.55%
Prepaid Expenses	0.96	0.89	0.66	0.87	0.77
Total Current Assets	24.25	10.45	20.53	36.57	57.94
Property, Plant & Equipment	1.19	1.59	0.98	0.55	0.64
Other Long-Term Assets	0.03	0.03	0.08	0.08	0.08
Total Assets	25.47	12.08	21.59	37.2	58.66
Accounts Payable	4.11	9.18	2.56	1.41	1.43
Accrued Expenses	3.48	-	2.91	2.44	2.01
Current Portion of Leases	0.08	0.06	0.05	0.14	0.12
Other Current Liabilities	1.72	16.12	5.98	-	-
Total Current Liabilities	9.39	25.36	11.5	3.99	3.56
Long-Term Leases	0.41	0.49	0.55	0.17	0.3
Total Liabilities	9.8	25.85	12.05	4.16	3.86
Common Stock	0	0	0	0	0
Additional Paid-In Capital	261.12	182.92	168.14	182.56	161.53
Retained Earnings	-247.34	-202.76	-159.99	-150.9	-126.78
Total Common Equity	13.77	-19.84	8.15	31.66	34.76
Shareholders' Equity	15.68	-13.78	9.54	33.05	54.79
Total Liabilities & Equity	25.47	12.08	21.59	37.2	58.66
Total Debt	0.49	0.55	0.6	0.3	0.42
Net Cash (Debt)	22.79	9.01	19.26	35.4	56.74
Net Cash Growth	152.94%	-53.22%	-45.59%	-37.61%	462.53%
Net Cash Per Share	0.61	0.74	2.73	6.38	28.64
Filing Date Shares Outstanding	46.08	32.26	9.74	6.11	5.05
Total Common Shares Outstanding	46.08	20.74	9.39	6.11	4.54
Working Capital	14.86	-14.91	9.03	32.58	54.38
Book Value Per Share	0.30	-0.96	0.87	5.18	7.65
Tangible Book Value	13.77	-19.84	8.15	31.66	34.76
Tangible Book Value Per Share	0.30	-0.96	0.87	5.18	7.65
Machinery	-	-	0.8	0.58	0.45
Leasehold Improvements	-	-	0.31	0.31	0.31

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q